

Graham L Radford-Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3376067/publications.pdf>

Version: 2024-02-01

159
papers

16,910
citations

36303

51
h-index

15266

126
g-index

164
all docs

164
docs citations

164
times ranked

23240
citing authors

#	ARTICLE	IF	CITATIONS
1	Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. <i>Nature</i> , 2012, 491, 119-124.	27.8	4,038
2	Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. <i>Nature Genetics</i> , 2010, 42, 1118-1125.	21.4	2,284
3	Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. <i>Nature Genetics</i> , 2011, 43, 246-252.	21.4	1,201
4	Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. <i>Lancet</i> , The, 2016, 387, 156-167.	13.7	607
5	Intestinal barrier dysfunction in inflammatory bowel diseases. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 100-113.	1.9	506
6	Crohn's disease management after intestinal resection: a randomised trial. <i>Lancet</i> , The, 2015, 385, 1406-1417.	13.7	475
7	Morphology of sporadic colorectal cancer with DNA replication errors. <i>Gut</i> , 1998, 42, 673-679.	12.1	422
8	Two-Year Combination Antibiotic Therapy With Clarithromycin, Rifabutin, and Clofazimine for Crohn's Disease. <i>Gastroenterology</i> , 2007, 132, 2313-2319.	1.3	339
9	Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. <i>Endoscopy</i> , 2009, 41, 618-637.	1.8	319
10	Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. <i>Gastroenterology</i> , 2016, 151, 110-119.	1.3	259
11	Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1037-1053.	3.7	225
12	Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. <i>Nature Genetics</i> , 2015, 47, 987-995.	21.4	218
13	Reduced α -defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease. <i>Gut</i> , 2008, 57, 903-910.	12.1	211
14	Role of diet in the development of inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 137-151.	1.9	199
15	Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression. <i>Nature Genetics</i> , 2020, 52, 160-166.	21.4	192
16	Common variants near ABCA1, AFAP1 and GMDS confer risk of primary open-angle glaucoma. <i>Nature Genetics</i> , 2014, 46, 1120-1125.	21.4	186
17	Deep Resequencing of GWAS Loci Identifies Rare Variants in CARD9, IL23R and RNF186 That Are Associated with Ulcerative Colitis. <i>PLoS Genetics</i> , 2013, 9, e1003723.	3.5	185
18	Hygiene hypothesis in inflammatory bowel disease: A critical review of the literature. <i>World Journal of Gastroenterology</i> , 2008, 14, 165.	3.3	178

#	ARTICLE	IF	CITATIONS
19	Protective role of appendectomy on onset and severity of ulcerative colitis and Crohn's disease. <i>Gut</i> , 2002, 51, 808-813.	12.1	171
20	HLA-DQA1 and HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. <i>Nature Genetics</i> , 2014, 46, 1131-1134.	21.4	165
21	Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. <i>Gut</i> , 2001, 48, 360-366.	12.1	163
22	Genome-wide association study of intraocular pressure uncovers new pathways to glaucoma. <i>Nature Genetics</i> , 2018, 50, 1067-1071.	21.4	152
23	CDP571, a humanised monoclonal antibody to tumour necrosis factor α , for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. <i>Gut</i> , 2004, 53, 1485-1493.	12.1	144
24	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. <i>Nature Genetics</i> , 2020, 52, 494-504.	21.4	138
25	Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients – a POCER study analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 867-879.	3.7	115
26	An intestinal epithelial defect conferring ER stress results in inflammation involving both innate and adaptive immunity. <i>Mucosal Immunology</i> , 2011, 4, 354-364.	6.0	114
27	Advances in IBD genetics. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 372-385.	17.8	114
28	Clinically active Crohn's disease in the presence of a low C-reactive protein. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 306-311.	1.5	110
29	Estimation and partitioning of (co)heritability of inflammatory bowel disease from GWAS and immunochip data. <i>Human Molecular Genetics</i> , 2014, 23, 4710-4720.	2.9	110
30	The Effect on Melanoma Risk of Genes Previously Associated With Telomere Length. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	109
31	A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn's Disease and Human Gut Microbiome Composition. <i>Gastroenterology</i> , 2016, 151, 724-732.	1.3	109
32	Chronic cigarette smoke exposure induces systemic hypoxia that drives intestinal dysfunction. <i>JCI Insight</i> , 2018, 3, .	5.0	103
33	Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1135-1140.	1.9	88
34	Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 149-158.	1.3	85
35	Chronic narcotic use in inflammatory bowel disease patients: Prevalence and clinical characteristics. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 1235-1238.	2.8	83
36	Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 294-302.	3.7	82

#	ARTICLE	IF	CITATIONS
37	NLRP1 restricts butyrate producing commensals to exacerbate inflammatory bowel disease. <i>Nature Communications</i> , 2018, 9, 3728.	12.8	81
38	ATG16L1 T300A Shows Strong Associations With Disease Subgroups in a Large Australian IBD Population: Further Support for Significant Disease Heterogeneity. <i>American Journal of Gastroenterology</i> , 2008, 103, 2519-2526.	0.4	79
39	Appendectomy and Tonsillectomy in Patients with Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 1995, 21, 283-286.	2.2	78
40	Serious infections in patients with inflammatory bowel disease receiving anti-tumour necrosis factor-alpha therapy: An Australian and New Zealand experience. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1732-1738.	2.8	78
41	Epidemiology of appendectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases. <i>Gut</i> , 2004, 53, 973-979.	12.1	70
42	CCR5-Δ32 mutation is strongly associated with primary sclerosing cholangitis. <i>Genes and Immunity</i> , 2004, 5, 444-450.	4.1	66
43	Granulocyte-Macrophage Colony-Stimulating Factor Autoantibodies. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1671-1680.	1.9	64
44	Airway Mucus Hyperconcentration in Non-Cystic Fibrosis Bronchiectasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 661-670.	5.6	64
45	Review article: acute severe ulcerative colitis – evidence-based consensus statements. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 127-144.	3.7	63
46	Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1169-1186.	1.9	63
47	KCNN4 Gene Variant Is Associated With Ileal Crohn's Disease in the Australian and New Zealand Population. <i>American Journal of Gastroenterology</i> , 2010, 105, 2209-2217.	0.4	59
48	Reciprocal relationship between the tumor suppressors p53 and BAX in primary colorectal cancers. <i>Oncogene</i> , 1998, 17, 2003-2008.	5.9	57
49	The IBD International Genetics Consortium Provides Further Evidence for Linkage to IBD4 and Shows Gene-Environment Interaction. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 1-7.	1.9	57
50	Cytokine gene expression in HIV-infected intestinal mucosa. <i>Aids</i> , 1994, 8, 1569-1576.	2.2	56
51	TNF-α and IL10 SNPs act together to predict disease behaviour in Crohn's disease. <i>Journal of Medical Genetics</i> , 2005, 42, 523-528.	3.2	56
52	Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1306-1312.	2.8	53
53	Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1248-1255.	4.4	53
54	Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy?. <i>Internal Medicine Journal</i> , 2001, 31, 146-150.	0.8	48

#	ARTICLE	IF	CITATIONS
55	10 Cytokines and inflammatory bowel disease. <i>Bailliere's Clinical Gastroenterology</i> , 1996, 10, 151-164.	0.9	47
56	Perspectives of paediatric and adult gastroenterologists on transfer and transition care of adolescents with inflammatory bowel disease. <i>Internal Medicine Journal</i> , 2014, 44, 490-496.	0.8	47
57	Associations between NOD2/CARD15 genotype and phenotype in Crohn's disease-Are we there yet. <i>World Journal of Gastroenterology</i> , 2006, 12, 7097.	3.3	47
58	Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e449-e456.	1.3	45
59	Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 17-27.	8.1	44
60	CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 617-628.	3.7	43
61	Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1017-1026.	3.7	43
62	Crohn's disease and smoking: Is it ever too late to quit?. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e665-e671.	1.3	43
63	Hypoxia and Integrin-Mediated Epithelial Restitution during Mucosal Inflammation. <i>Frontiers in Immunology</i> , 2013, 4, 272.	4.8	43
64	Body composition and muscle strength as predictors of bone mineral density in Crohn's disease. <i>Journal of Bone and Mineral Metabolism</i> , 2009, 27, 456-463.	2.7	38
65	Genetic Susceptibility in IBD. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 240-245.	1.9	37
66	Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 542-552.	3.7	37
67	Predicting response after infliximab salvage in acute severe ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1347-1352.	2.8	37
68	Performance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score method. <i>BMC Medical Genetics</i> , 2017, 18, 94.	2.1	36
69	Novel NOD2 haplotype strengthens the association between TLR4 Asp299gly and Crohn's disease in an Australian population. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 585-590.	1.9	35
70	Selenoprotein S is a marker but not a regulator of endoplasmic reticulum stress in intestinal epithelial cells. <i>Free Radical Biology and Medicine</i> , 2014, 67, 265-277.	2.9	34
71	Bone Loss in Crohn's Disease: Exercise As a Potential Countermeasure. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 1108-1118.	1.9	32
72	Clinical pharmacology of AMG 181, a gut-specific human anti-IL-17 monoclonal antibody, for treating inflammatory bowel diseases. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1315-1333.	2.4	32

#	ARTICLE	IF	CITATIONS
73	Effect of Intestinal Resection on Quality of Life in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 452-462.	1.3	30
74	Angiotensinogen and transforming growth factor $\hat{A}1$: novel genes in the pathogenesis of Crohn's disease. <i>Journal of Medical Genetics</i> , 2006, 43, e51-e51.	3.2	28
75	Food avoidance in outpatients with Inflammatory Bowel Disease – Who, what and why. <i>Clinical Nutrition ESPEN</i> , 2019, 31, 10-16.	1.2	28
76	Treatment of steroid refractory inflammatory bowel disease (IBD) with mycophenolate mofetil (MMF). <i>Australian and New Zealand Journal of Medicine</i> , 1998, 28, 344-345.	0.5	27
77	Thiopurine Therapy in Inflammatory Bowel Diseases: Making New Friends Should Not Mean Losing Old Ones. <i>Gastroenterology</i> , 2019, 156, 11-14.	1.3	27
78	High Vitamin D – Binding Protein Concentration, Low Albumin, and Mode of Remission Predict Relapse in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2456-2464.	1.9	26
79	Regulation of IL-12p40 by HIF controls Th1/Th17 responses to prevent mucosal inflammation. <i>Mucosal Immunology</i> , 2017, 10, 1224-1236.	6.0	26
80	IL23R-Protective Coding Variant Promotes Beneficial Bacteria and Diversity in the Ileal Microbiome in Healthy Individuals Without Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 451-461.	1.3	23
81	Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 653-661.	1.3	22
82	Co-existence of Network Architectures Supporting the Human Gut Microbiome. <i>IScience</i> , 2019, 22, 380-391.	4.1	22
83	The Fas counterattack is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instability. <i>Human Pathology</i> , 2008, 39, 243-250.	2.0	21
84	Surgical outcomes in steroid refractory acute severe ulcerative colitis: the impact of rescue therapy. <i>Colorectal Disease</i> , 2013, 15, 374-379.	1.4	21
85	A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies. <i>American Journal of Human Genetics</i> , 2016, 98, 857-868.	6.2	21
86	Serologic antibodies in relation to outcome in postoperative Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1195-1203.	2.8	21
87	Randomized, Placebo Controlled Trial of Experimental Hookworm Infection for Improving Gluten Tolerance in Celiac Disease. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00274.	2.5	21
88	Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 93-102.	1.9	20
89	Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy. <i>World Journal of Gastroenterology</i> , 2016, 22, 9104.	3.3	20
90	Will worms really cure Crohn's disease?. <i>Gut</i> , 2005, 54, 6-8.	12.1	19

#	ARTICLE	IF	CITATIONS
91	The use of indigocarmine spray increases the colonoscopic detection rate of adenomas. <i>Journal of Gastroenterology</i> , 2009, 44, 826-833.	5.1	19
92	Protective effects of <i>Helicobacter pylori</i> for IBD are related to the <i>cagA</i> -positive strain. <i>Gut</i> , 2018, 67, 393-394.	12.1	19
93	ACE inhibitors and angiotensin II receptor antagonists in Crohn's disease management. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 645-651.	3.0	18
94	Smoking behaviour modifies IL23-associated disease risk in patients with Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 299-307.	2.8	18
95	Accurate Imputation-Based Screening of Gln368Ter Myocilin Variant in Primary Open-Angle Glaucoma. , 2015, 56, 5087.		17
96	Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status. <i>Journal of Pathology</i> , 2003, 201, 46-54.	4.5	15
97	A randomized, placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF- α , in patients with moderate to severe Crohn's disease. <i>Gastroenterology</i> , 2003, 124, A61.	1.3	14
98	Inter-observer agreement for Crohn's disease sub-phenotypes using the Montreal Classification: How good are we? A multi-centre Australasian study. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 287-293.	1.3	14
99	Markers of Systemic Inflammation in Acute Attacks of Ulcerative Colitis: What Level of C-reactive Protein Constitutes Severe Colitis?. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1089-1096.	1.3	14
100	Can Capsule Endoscopy Help Differentiate the Aetiology of Indeterminate Colitis?. <i>Gastrointestinal Endoscopy</i> , 2004, 59, P177.	1.0	13
101	1161 Adalimumab Prevents Post-Operative Crohn's Disease Recurrence, and is Superior to Thiopurines: Early Results From the POCER Study. <i>Gastroenterology</i> , 2012, 142, S-212.	1.3	13
102	Drain fluid amylase as a sensitive biomarker for the early detection of anastomotic leakage in ileal pouch surgery. <i>Colorectal Disease</i> , 2019, 21, 460-464.	1.4	13
103	Detectable Laboratory Abnormality Is Present up to 12 Months Prior to Diagnosis in Patients with Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2019, 64, 503-517.	2.3	13
104	Crohn's disease is facilitated by a disturbance of programmed death-1 ligand 2 on blood dendritic cells. <i>Clinical and Translational Immunology</i> , 2019, 8, e01071.	3.8	12
105	Microbiota links to neural dynamics supporting threat processing. <i>Human Brain Mapping</i> , 2022, 43, 733-749.	3.6	12
106	3 Ulcerative colitis: an immunological disease?. <i>Bailliere's Clinical Gastroenterology</i> , 1997, 11, 35-52.	0.9	11
107	Mycophenolate mofetil in IBD patients. <i>Lancet, The</i> , 1999, 354, 1386-1387.	13.7	11
108	Associations of NOD2 polymorphisms with Erysipelotrichaceae in stool of in healthy first degree relatives of Crohn's disease subjects. <i>BMC Medical Genetics</i> , 2020, 21, 204.	2.1	11

#	ARTICLE	IF	CITATIONS
109	Crohn's Colitis Care (CCCare): bespoke cloud-based clinical management software for inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1419-1426.	1.5	11
110	Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 735-740.	1.6	10
111	Ileal Pouch-Anal Anastomosis for Ulcerative Colitis: An Australian Institution's Experience. <i>Annals of Coloproctology</i> , 2021, 37, 318-325.	2.0	10
112	Cytokine gene transcription of human colonic intraepithelial lymphocytes costimulated with epithelial cells bearing HLA-DR and its inhibition by 5-aminosalicylic acid. <i>Journal of Clinical Immunology</i> , 1996, 16, 237-241.	3.8	9
113	A rolling phenotype in Crohn's disease. <i>PLoS ONE</i> , 2017, 12, e0174954.	2.5	9
114	312 The First Validated Post-Operative Endoscopic Crohns Disease Index: The POCER Index. Identification of Key Endoscopic Prognostic Factors. <i>Gastroenterology</i> , 2016, 150, S72.	1.3	8
115	Altered Expression of Angiotensinogen and Mediators of Angiogenesis in Ileal Crohn's Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 39-48.	0.9	8
116	PACSIN2 Does Not Influence Thiopurine-Related Toxicity In Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2014, 109, 925-927.	0.4	7
117	Su1762 Clinical and Molecular Characterization of Medically Refractory Acute, Severe Colitis: Preliminary Results From the International Inflammatory Bowel Disease Genetics Consortium (IIBDGC) ImmunoChip Study. <i>Gastroenterology</i> , 2013, 144, S-470.	1.3	6
118	The effect of pre-admission immunosuppression on colectomy rates in acute severe ulcerative colitis. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481880978.	3.2	6
119	Tumor necrosis factor- γ haplotype is strongly associated with bone mineral density in patients with Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 913-919.	2.8	5
120	Level of UV Exposure, Skin Type, and Age Are More Important than Thiopurine Use for Keratinocyte Carcinoma Development in IBD Patients. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1172-1179.	2.3	5
121	Dietary intake of patients with inflammatory bowel disease aligns poorly with traditional Mediterranean diet principles. <i>Nutrition and Dietetics</i> , 2022, 79, 229-237.	1.8	5
122	The significance of pANCA in inflammatory bowel disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 863-864.	2.8	4
123	A randomised multicentre comparison of pantoprazole quadruple and triple therapies versus bismuth triple therapy in H. pylori positive, endoscopy negative dyspepsia. <i>Gastroenterology</i> , 2000, 118, A879.	1.3	4
124	Nonsynonymous Polymorphism in Guanine Monophosphate Synthetase Is a Risk Factor for Unfavorable Thiopurine Metabolite Ratios in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2606-2612.	1.9	4
125	Telehealth in inflammatory bowel disease. <i>Internal Medicine Journal</i> , 2020, , .	0.8	4
126	Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol. <i>BMJ Open</i> , 2021, 11, e043921.	1.9	4

#	ARTICLE	IF	CITATIONS
127	633 The Relative Abundances of Dorea and Faecalibacterium spp. in the Mucosa Associated Microbiome of Newly Diagnosed Children With Crohn's Disease Are Differentially Affected by Exclusive Enteral Nutrition. <i>Gastroenterology</i> , 2016, 150, S132-S133.	1.3	3
128	Development and evaluation of a risk assessment tool to improve clinical triage accuracy for colonoscopic investigations. <i>BMC Cancer</i> , 2018, 18, 229.	2.6	3
129	Short-term colectomy is avoided in over half of regional patients failing medical therapy for acute severe ulcerative colitis with co-ordinated transfer and tertiary care. <i>Internal Medicine Journal</i> , 2020, 50, 823-829.	0.8	3
130	A validated risk stratification tool for detecting high-risk small bowel Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 281-290.	3.7	3
131	Nudix Hydrolase 15 loss-of-function variants in an Australian Inflammatory Bowel Disease population. <i>Internal Medicine Journal</i> , 2022, , .	0.8	3
132	The Use of Indigocarmine Spray Increases the Colonoscopic Detection Rate of Flat Adenomas and Large Sessile Hyperplastic Polyps. <i>Gastrointestinal Endoscopy</i> , 2004, 59, P96.	1.0	2
133	Commentary: salvage medical therapy for acute severe colitis - ciclosporin or infliximab? Author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 989-989.	3.7	2
134	UV Exposure and Skin Type are More Important than Thiopurine Exposure for Non-Melanoma Skin Cancer Risk in IBD. <i>Gastroenterology</i> , 2017, 152, S576.	1.3	2
135	Editorial: faecal microbiota transplantation for ulcerative colitis "not quite there yet?". <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 630-631.	3.7	2
136	Evaluating a risk assessment tool to improve triaging of patients to colonoscopies. <i>Internal Medicine Journal</i> , 2019, 49, 1292-1299.	0.8	2
137	Common PPAR β variants C161T and Pro12Ala are not associated with inflammatory bowel disease in an Australian cohort. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2012, 21, 349-55.	0.9	2
138	Anti-tumour necrosis factor- α treatment for perianal Crohn's disease in Australia. <i>Medical Journal of Australia</i> , 2010, 192, 375-377.	1.7	1
139	Smoking Cessation Following the Diagnosis of Crohn's Disease Still Reduces the Rates of Surgery and Complicated Disease. <i>Gastroenterology</i> , 2011, 140, S-429.	1.3	1
140	Clinical Remission After Stopping Infliximab in Crohn's Disease: Is All That Glitters True Gold?. <i>Gastroenterology</i> , 2012, 142, e17.	1.3	1
141	Sa1924 Colectomy Free Survival in Patients With Acute Severe Ulcerative Colitis (ASUC): Analysis of Outcomes Based on Presentation to a Regional Hospital Versus a Metropolitan Hospital. <i>Gastroenterology</i> , 2016, 150, S405.	1.3	1
142	Editorial: obesity management and IBD "weight loss reduces IBD risk. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 731-732.	3.7	1
143	Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin Psoriasis. <i>Rheumatology and Therapy</i> , 2021, 8, 1603-1616.	2.3	1
144	Multicenter Study of Drain Fluid Amylase as a Biomarker for the Detection of Anastomotic Leakage After Ileal Pouch Surgery Without a Diverting Ileostomy. <i>Diseases of the Colon and Rectum</i> , 2022, 65, 1335-1341.	1.3	1

#	ARTICLE	IF	CITATIONS
145	Editorial: is older-onset ulcerative colitis more severe or less aggressively managed?. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1350-1351.	3.7	1
146	NOD2 Gene mutations are associated with different clinical phenotypes in patients with Crohn disease. <i>Gastroenterology</i> , 2003, 124, A376.	1.3	0
147	Does the Use of Indigocarmine Spray Increase the Colonoscopic Detection Rate of Advanced Adenomas?. <i>Gastrointestinal Endoscopy</i> , 2005, 61, AB265.	1.0	0
148	How useful are biomarkers for the prediction of short-term relapse in patients with Crohn's disease?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007, 4, 72-73.	1.7	0
149	Outcomes of salvage therapy for acute severe ulcerative colitis: Cyclosporin versus Infliximab. <i>Inflammatory Bowel Diseases</i> , 2009, 15, S43-S44.	1.9	0
150	Letter: ciclosporin or infliximab in acute ulcerative colitis - still undecided; authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 993-993.	3.7	0
151	Response to Magro et al.. <i>American Journal of Gastroenterology</i> , 2015, 110, 931-932.	0.4	0
152	Sa1964 Weight-Based Dosing of Thiopurines and 6-TGN Concentrations in an Adult Cohort of Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2016, 150, S418.	1.3	0
153	Sa1923 Oral Corticosteroid Use at Time of Admission Is Associated With an Increased Late Colectomy Rate in Patients With Acute Severe Ulcerative Colitis (ASUC). <i>Gastroenterology</i> , 2016, 150, S404-S405.	1.3	0
154	Sa1884 Risk Factors Predicting Recurrent Ileal Resections in Patients with Crohn's Disease. <i>Gastroenterology</i> , 2016, 150, S391-S392.	1.3	0
155	Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 856-857.	3.7	0
156	Regulation of IL-12P40 by HIF Controls TH1/TH17 Responses to Prevent Mucosal Inflammation. <i>Gastroenterology</i> , 2017, 152, S567-S568.	1.3	0
157	Editorial: first among Equals – not for either infliximab or adalimumab in Crohn's disease – yet. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1225-1226.	3.7	0
158	Head-to-head trials in inflammatory bowel disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 18-19.	2.8	0
159	Letter: hidden costs in healthcare use for incident and prevalent Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 368-369.	3.7	0